Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.

IF 0.7 Q4 SURGERY Journal of radiosurgery and SBRT Pub Date : 2022-01-01

Rashad Rzazade, Ngoc T Pham, Menekse Turna, Mehmet Dogu Canoglu, Esra Kucukmorkoc, Kezban Berberoglu, Hale Basak Caglar

{"title":"Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.","authors":"Rashad Rzazade, Ngoc T Pham, Menekse Turna, Mehmet Dogu Canoglu, Esra Kucukmorkoc, Kezban Berberoglu, Hale Basak Caglar","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer (51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED10, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"8 4","pages":"275-282"},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322168/pdf/rsbrt-8-275.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.

Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer (51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED₁₀, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.

Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.

Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.

Abstract Image

微信好友朋友圈 QQ好友复制链接

本刊更多论文

立体定向放射治疗肾上腺转移性少转移性及少进展性肺癌。

目的:评价立体定向放射治疗(SBRT)治疗少转移肺癌肾上腺转移(AGM)的疗效和安全性。方法:2013年6月至2021年5月，44例低转移性肺癌患者(51例AGMs)接受SBRT治疗。46例(90%)病变接受100 Gy的生物有效剂量(BED10， α/β = 10)。主要终点为局部控制(LC)。采用Kaplan-Meier法计算局部控制(LC)、总生存(OS)和无进展生存(PFS)曲线。结果:中位随访时间为23个月。最常见的组织学为非小细胞肺癌(88.6%)。1年和2年的贷款利率分别为95%和91%。单因素分析显示，孤立性AGMs患者的总生存率更高。结论:本研究表明，在低转移性肺癌AGM患者中，高BED的SBRT与令人满意的LC和低毒性率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of radiosurgery and SBRT SURGERY-

CiteScore

1.40

自引率

8.30%

发文量